InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2023-03-28 00:00:00 ET · period of report 2023-03-24 · accession 0001209191-23-021443 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-28 2023-03-24+ TYRA Harris Todd CEO, Dir S - Sale+OE $16.00 -5,912 1.70M -0.3% -$94.6K
DM 2023-03-28 2023-03-24+ TYRA Harris Todd CEO, Dir M - OptEx $2.25 +5,912 1.70M +0.3% +$13.3K
DM 2023-03-28 2023-03-24+ TYRA Harris Todd CEO, Dir M - OptEx $0.00 -5,912 409.6K -1% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-28 S D 2,779 $16.00 1,701,276 D — —
2 Common Common Stock 2023-03-27 M A 2,963 $2.25 1,704,239 D — —
3 Common Common Stock 2023-03-24 S D 170 $16.00 1,701,276 D — —
4 Common Common Stock 2023-03-24 M A 170 $2.25 1,701,446 D — —
5 Common Common Stock 2023-03-27 S D 2,963 $16.00 1,701,276 D — —
6 Common Common Stock 2023-03-28 M A 2,779 $2.25 1,704,055 D — —
7 Derivative Stock Option (Right to Buy) 2023-03-28 M D 2,779 $0.00 403,864 D $2.25 · — to 2031-03-09 2,779 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
8 Derivative Stock Option (Right to Buy) 2023-03-27 M D 2,963 $0.00 406,643 D $2.25 · — to 2031-03-09 2,963 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
9 Derivative Stock Option (Right to Buy) 2023-03-24 M D 170 $0.00 409,606 D $2.25 · — to 2031-03-09 170 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.